Episode
Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
- Podcast
- Business Of Biotech
- Published
- Apr 27, 2026
- Duration seconds
- 2857
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries. Adam talks about his strategy for the company after becoming CEO last July, including moving company trading from Canada's TSX Venture Exchange to the NASDAQ for better visibility, and making key hires for growt...